Relay’s managing directors, Brigham Hyde and Dave Greenwald, recently returned from the JP Morgan Healthcare Conference 2013 (JPM). The conference was abuzz with a fresh sense of optimism and excitement that hasn’t been seen in the biopharma industry in recent memory. From management teams to seasoned executives and venture capitalists, the change in attitude and …
By John Carroll Chris Viehbacher (photo) wasn’t playing around when he said that Sanofi-Aventis ($SNY) was going to turn to outside partners for more of its innovative thinking. He spent much of 2010 breaking the old mold on drug research while trying to forge a new one. In the process, he became the world leader in innovation. …
By Tracy Staton The mega-merger was so 2009. This year was the year of the mini-merger; of many mini-mergers, in fact. As drugmakers continued their scramble to replace revenues lost or soon-to-be-lost to generic competition, they made their deals in sips and nibbles. Think cocktail party rather than sit-down, seven-course meal; a few hundred million …
By Tracey Staton It’s been a busy decade for pharma dealmaking. During the 10 years that ended Dec. 31, 2009, a total of 1,345 mergers and acquisitions of pharmaceutical assets and companies were announced, with disclosed prices totaling more than $694 billion, according to DealSearchOnline.com. The biggest deal: GlaxoWellcome’s $74 billion merger with SmithKline Beecham …
